At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 149 enrolled
Drug / intervention
Ixekizumab +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Randomized, Double-Blind Study Comparing the Efficacy and Safety of Ixekizumab Versus Placebo in Patients With Moderate-to-Severe Genital Psoriasis
In Brief
A Phase 3 clinical trial evaluating Ixekizumab and Placebo for Genital Psoriasis and Psoriasis. Completed, enrolled 149 participants across 34 sites in 8 countries.
Detailed Summary
The main purpose of this study is to evaluate the efficacy and safety of the study drug ixekizumab compared to placebo in participants with moderate-to-severe genital psoriasis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGenital Psoriasis, Psoriasis
CountriesAustralia, Austria, Belgium, Canada, Netherlands, Puerto Rico, Turkey (Türkiye), United States
Collaborators--
Timeline
Phase 3CompletedFinished
20162017201820192020202120222023202420252026
First PostedMar 2016
Enrollment StartApr 2016
Primary CompletionFeb 2017
Study CompletionFeb 2018
TodayJul 2026
First PostedMar 24, 2016
Enrollment StartApr 1, 2016
Primary CompletionFeb 22, 2017
Study CompletionFeb 21, 2018
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 10.3 years ago
Interventions
Ixekizumabdrug
Administered SC
Placebodrug
Administered SC